AbCellera Biologics Inc. (ABCL) Earnings Call Transcript
November 9, 2026
Earnings Call Speaker Segments
Hi, everyone, and thanks for being with us on AbCellera's Q3 2026 earnings call. I'm Tryn Stimart, Chief Legal and Compliance Officer at AbCellera. On the call today we have Dr. Carl Hansen, AbCellera's President and CEO; Dr. Sarah Noonberg, our Chief Medical Officer; and Andrew Booth, our Chief Financial Officer. Today we may discuss strategic priorities and the financial outlook, based on what we currently expect and consistent with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Those statements carry a number of risks, uncertainties, and other factors that might make actual results differ materially from what we describe. For a more detailed discussion of these risks, please review the risk factors section in our most recent Form 10-K and in our subsequent 10-Q filings with the SEC. AbCellera undertakes no obligation to update any forward-looking statements to reflect events or circumstances occurring after today's date. Today's presentation, along with our earnings press release and our SEC filings, can be found on our Investor Relations website. Information we give about our pipeline is meant for the investment community and is not promotional. As we move into our prepared remarks, please be aware that this call is being recorded and will be available for replay on our Investor Relations website, and that every dollar figure mentioned during the call is in U.S. dollars. Following our prepared remarks, we'll open the line for questions and answers. I'll now hand the call over to Carl.
Thanks, Tryn. And I appreciate everyone joining us today. For AbCellera, the third quarter marked a major turning point, largely driven by encouraging topline Phase 2 results for ABCL635, an investigational antibody being developed as a non-hormonal option for moderate to severe vasomotor symptoms, commonly known as hot flashes. That Phase 2 trial was set up to assess both efficacy and safety four weeks after a single 600 mg injection of ABCL635. The findings, which we made public on August 10th, indicate that ABCL635 holds substantial promise for reshaping how hot flashes are treated without hormones. This data gives us a genuine chance to create what might turn into a category-defining product in women's health—one that stands apart clearly when it comes to efficacy, safety, and convenience. In that same vein, we believe our data considerably widen the commercial potential for ABCL635, and we are entirely dedicated to advancing it into late-stage development next year. Across the next few slides, I'll go through the main results and put them in context alongside therapies that already exist. Our first key efficacy endpoint involved lowering how frequently moderate and severe hot flashes happen. This slide shows you how ABCL635 did when it was measured as a change from baseline. The left side presents the primary analysis, covering only weeks 2, 3, and 4, while the right side shows a pre-specified sensitivity analysis that also incorporated week 1 data. First, I'd point out that the data reveal a rapid onset of benefit — by week 1 there was already a significant placebo-adjusted treatment difference of 2.6 events — with improvements continuing to grow across the entire 4-week period. By week 4, the ABCL635 arm showed a mean reduction of 8.8 events per day, whereas the placebo arm showed a mean reduction of just 3.5 events per day, which works out to a placebo-adjusted treatment difference of 5.3 events. If you examine the percentage change from baseline, daily events fell by 83% in the ABCL635 arm versus a 33% decrease in the placebo arm, yielding a placebo-adjusted treatment difference of 50%. Of note, the benefit observed with ABCL635 proved highly consistent in subgroup analyses, and the data remained robust across a range of sensitivity analyses. Reduction in VMS severity served as our second key efficacy endpoint, measured on a 3-point scale for mild, moderate, and severe events. As with frequency, benefit appears rapidly, with meaningful improvement by the 1-week time point and further gains through 4 weeks. Looking at week four, the average severity score dropped 1.4 points among those on ABCL635, compared with a 0.3-point decline in the placebo arm — a placebo-adjusted gap of 1.1 points. As a percentage change from baseline, that works out to a mean 58% reduction in severity for the ABCL635 group versus 12% for placebo, giving a placebo-adjusted difference of 46%. Rather than looking only at population averages, it's also helpful to see how many patients landed in different ranges of treatment benefit. The table on the left indicates that 37% of ABCL635 participants had complete, meaning 100%, resolution of moderate or severe events by week four, while only 2.2% of placebo patients did. As far as we know, no non-hormonal VMS treatment has ever shown complete resolution rates like these for moderate and severe events, and these results are at minimum on par with—perhaps superior to—what hormone therapy studies have reported. Also, almost 61% of ABCL635 participants experienced a 90%-or-greater drop from baseline in moderate to severe event counts, versus just 8.7% of those on placebo, and fully 78%—over three-quarters of patients—reached a reduction exceeding 75%. Comparable benefits, large and clinically meaningful, appeared for severity too, as the table on the right illustrates. Although we recognize that comparing across trials has its limitations, it is still useful to assess the treatment effects we observed against similarly collected 4-week data from the registrational trials of the two approved small-molecule NK3R antagonists, fezolinetant and elinzanetant. When we look at the placebo-adjusted decrease in how often moderate and severe VMS occur, stated as a percentage of baseline levels, the placebo-adjusted treatment effect we found is 50%, approximately double the 20% to 25% reductions described in Phase 3 studies of fezolinetant and elinzanetant. A still larger gap in treatment effect appeared for improvements in VMS severity, where the benefit was roughly 3.5- to 5-fold greater than in the registrational studies of fezolinetant and elinzanetant. What matters here is that these much stronger treatment results came about with no obvious indication of toxicity in the gut or the liver. On this slide, you'll see the adverse events that were reported for at least two patients in either arm, whatever the relationship to treatment, and that happened within the first four weeks. Across the whole dataset, ABCL635 showed a tolerability profile that was favorable. In general, the number of patients who had at least one adverse event was numerically higher in the ABCL635 arm than in the placebo arm. Looking at the ABCL635 arm, we didn't see any serious or severe adverse events. On the placebo side, though, one patient experienced a serious adverse event and two had severe ones. Headaches were reported more often with ABCL635, which lines up with the Phase 1 findings, and in both arms the majority of those were mild and resolved quickly. Fatigue was also reported more frequently among those receiving ABCL635, but all of those cases were mild. The important takeaway is that no gastrointestinal toxicity emerged in this study, despite that side effect being a consistent feature of the two approved small-molecule NK3R inhibitors. In fact, the ABCL635 arm had fewer instances of nausea, and no diarrhea or abdominal pain cases at all, while a number of placebo patients did report such events. To summarize, the Phase 2 results demonstrated robust efficacy together with dependable tolerability. Given that, we believe ABCL635 has the potential to transform the way non-hormonal hot flash treatment is provided. Looking forward, we are dedicated to advancing ABCL635 into late-stage development, and we are working actively with the FDA's Model-Informed Drug Development, or MIDD, program so we can reach alignment on dose selection for the subsequent studies. We intend to share additional data covering 12 weeks, as well as open-label extension, or OLE, findings, in early 2027. As a reminder on efficacy, the Phase 2 trial's primary goal was assessing the benefit of one dose of ABCL635 across 4 weeks. That is the data we just walked through. The rest of the 12-week data serves to track how efficacy declines during the final 8-week washout period, and it will support exposure-response modeling for late-stage dose selection. After the initial 12-week period, OLE data will add a 4-week assessment, letting us characterize repeat-dose dynamics in the treatment group together with initial active exposure among placebo patients. We expect to launch late-stage development for menopause VMS in 2027. Beyond that, we're expanding the range of conditions ABCL635 targets to include hot flashes caused by hormone suppression in breast and prostate cancer treatment, and we anticipate launching clinical trials in both of those patient groups during 2027. Finally, we're pleased to unveil a new program today: ABCL992, a next-generation half-life extended analog of ABCL635. IND-enabling work on ABCL992 got underway in Q3. Leveraging the landmark data generated with ABCL635, we think this program will deliver an additional therapeutic choice that gives patients substantially more convenience through a longer dosing interval while allowing us to serve a larger patient population. Moving on from ABCL635, and consistent with prior guidance, we are sharing today the Phase 1 data for ABCL575, our second clinical candidate—a long-acting investigational antibody that targets OX40 ligand. ABCL575's clinical program started out as a possible best-in-class follow-on to Sanofi's amlitelimab, which at the time was undergoing Phase 3 trials in atopic dermatitis. Early this year, disappointing clinical results emerged, and that led to amlitelimab's development being stopped in atopic dermatitis. Separately, late-stage trials of Amgen's rocatinlimab—an antibody that targets OX40—were likewise discontinued. Given those external developments, we have chosen not to continue developing ABCL575 in atopic dermatitis. Although we believe the OX40/OX40 ligand class could hold promise for additional autoimmune conditions, right now we don't plan to advance it beyond Phase 1. I'll pass things along to Sarah now, and she'll take us through the topline results from that Phase 1 study. Sarah?
Thank you, Carl. Even with the difficulties seen across the OX40/OX40 ligand category, the topline data from our Phase 1 trial of ABCL575 showed tolerability and a PK profile that came out favorable and aligned very closely with what we set as our target product profile. As a reminder, this Phase 1 trial was randomized, double-blind, placebo-controlled, and single-ascending-dose, enrolling 40 healthy volunteers between 18 and 65 years old. Randomization was 3 to 1, with participants getting one subcutaneous dose of ABCL575 ranging from 75 mg to 900 mg, or matching placebo. Because ABCL575 is expected to have a long half-life, participants were tracked for roughly 1 year. Safety, tolerability, and pharmacokinetics were the study endpoints. What we have here is close to the full dataset, with the last few participants finishing up their final study visit. Thirty participants received one dose of ABCL575, and ten received a single dose of placebo. Across the study overall, men and women were distributed about equally, and participants were 44 years old on average. There were no clinically meaningful imbalances between the treatment groups. In this dataset, ABCL575 demonstrated a favorable tolerability profile. This slide provides a summary of adverse events reported by two or more participants in either treatment arm, irrespective of whether they were related to treatment. In the ABCL575 arm, there were no serious or severe adverse events, while the placebo arm had one severe adverse event. Across both treatment arms, the overall rate of adverse events came out similar: roughly 57% of those receiving ABCL575 reported one or more adverse events, versus 60% among placebo recipients. The adverse events seen most often were injection site reactions and headache; these did not vary with dose and did not differ notably between the ABCL575 and placebo arms. Nothing in the safety data from this dataset pointed to immune suppression of clinical importance. Turning to pharmacokinetics, ABCL575 demonstrated sustained exposure that was roughly proportional to dose throughout the range tested. From what we can see in the data so far, the average half-life came out to roughly 55 days — it went from 43 days in the lowest-dose group up to 79 days in the 600 mg group. That lines up with the 57-day mean half-life our preclinical work had projected. We also benchmarked our exposures against an efficacy target of 4 mcg/mL, a threshold derived from published amlitelimab clinical data. At clinically relevant doses, exposure stayed comfortably above that level for more than 12 weeks. All of this together supports giving the drug once every three months or even less often, and that was a central element of our target product profile. To sum up, the Phase 1 trial achieved its main endpoints, among them a tolerability and PK profile that was favorable and enabled a longer interval between doses. As Carl noted, given outside developments involving the OX40/OX40 ligand class, we have decided not to advance clinical development any further right now. My thanks go to the participants in the study, the investigators, and the site teams for what they contributed and their dedication to this work. I'll now hand the call back to Carl, who can provide further corporate development updates for the quarter.
Thanks, Sarah. After just going through the clinical data for ABCL635 and ABCL575, I want to step back and offer some context on what these results mean for AbCellera. Slightly more than a year ago, we were conducting preclinical work and striving to complete the hard shift from a platform organization into a clinical biotech. As of today, we have guided our first two programs successfully through early-stage clinical development; with ABCL635, we have produced breakthrough results that create a route toward a transformative product in women's health. By next year, AbCellera will become a late-stage clinical development company. Clinical success has opened up an exciting opportunity, and seizing that opportunity takes resources. After we released our Phase 2 data for ABCL635, we closed a heavily oversubscribed $200 million capital raise. With a stronger balance sheet, we can move ABCL635 into late-stage development while we keep investing in our wider pipeline. Now, on that pipeline: although investor attention has been overwhelmingly concentrated on ABCL635, we think this is only the first instance of our platform generating value. Our aim is to demonstrate that by repeatedly inventing and developing programs that stress innovation and that carry potential to become breakthrough medicines. Today we have multiple pipeline updates. First, the programs we previously disclosed, ABCL688 and ABCL386, are still moving through IND-enabling activities. As noted earlier, we have added a new program, ABCL992, a next-generation form of ABCL635 engineered for less frequent dosing. Today we are also announcing two more programs: ABCL385, a new program for an undisclosed oncology indication; and ABCL646, a potential first-in-class antibody antagonist against an undisclosed ion channel target. As with earlier programs, we do not expect to reveal further details on ABCL385 and ABCL646 until they reach clinical development. To sum up, Q3 was a breakthrough quarter for AbCellera. We produced compelling clinical data for ABCL635 that lays the groundwork for late-stage development next year. At the same time, we finished our studies of ABCL575 successfully, have moved ABCL688 and ABCL386 forward, and have added three new programs, ABCL992, ABCL385, and ABCL646, to our pipeline. With these achievements, we have successfully met all our stated 2026 corporate priorities; with our financing complete, we are in a very strong financial position as we close out 2026, and we expect that 2027 will be another significant year for AbCellera. With that, I'll pass it to Andrew to cover our financials. Andrew?
Thanks, Carl. As Carl noted, AbCellera remains in a solid liquidity spot, holding more than $790 million in cash and equivalents, along with over $100 million in committed government funding that's available to carry out our strategy. We keep executing against our plans, concentrating on internal programs and making use of our process development and clinical manufacturing investments. Moving to revenues and expenses: revenue for the quarter came in above $10 million, versus total revenue of roughly $9 million in the same quarter of 2025. Research fees made up most of this quarter's revenue. Our R&D expenses for the quarter were about $44 million, reflecting our continued emphasis on investing in internal programs. R&D spending in last year's same quarter ran approximately $12 million higher, driven by a couple of specific internal program investments in Q3 of 2025. On SG&A, expenses came to roughly $14 million, down from $25 million last year. That sizable drop in SG&A ties to the wrap-up of our intellectual property litigation and to team changes made after narrowing our focus on the internal pipeline. On earnings, we're reporting a net loss of about $41 million for Q3 of 2026, versus a loss of roughly $57 million a year earlier. On a per-share basis, that comes to a loss of 13 cents, both basic and diluted. Turning to cash flows, we ended the quarter with more than $790 million in cash and marketable securities. Operating activities generated $19 million in cash across the first 9 months of the year. That operating cash flow includes receipt of upfront payments from our TCE deals with Jazz and Vertex, plus the Bruker litigation settlement paid out in 2026. As Carl mentioned, during the quarter we closed our oversubscribed $200 million equity raise. Proceeds from that raise, together with government funding and employee stock option exercises, brought $214 million in financing cash inflows. Excluding marketable securities, investment activities so far this year included approximately $8 million in capital expenditures, offset by a similar amount in government grants received. Under our treasury strategy, we now hold about $600 million in short-term marketable securities. Investment activities for the quarter included a $197 million net investment in those holdings. As a reminder, we've received funding commitments to advance our internal pipeline from the Government of Canada's Strategic Innovation Fund and the Government of British Columbia. That available capital isn't reflected on our balance sheet. We hold more than $790 million in cash and equivalents, and when you add the portion of our secured government funding that remains unused, our available liquidity comes to over $890 million for carrying out our strategy. Beyond that, we have additional liquidity available through the other lab and office building we own in Vancouver, along with our GMP facility; as for company expenditures overall, our capital requirements are quite manageable, and we remain of the view that our liquidity is sufficient to fund pipeline investments for at least the next 3 years. With that, we'll be glad to take your questions. Operator?
Hey everyone. I really appreciate you taking my question, and congratulations on everything you've accomplished during the last quarter. I understand that you shared 635 — the 635 data — at two conferences during that quarter, after the disclosure. Could you tell us what kind of feedback you received from clinicians out in the field, and how excited they seem to be, and even more importantly, what you learned from those clinicians that helps shape your thinking about the next steps for developing this asset? Thanks very much.
Hello, Evan. Appreciate the question. Honestly, the reception we received was remarkable at both IMS in Rio and TMS, The Menopause Society, in San Diego last month. What we heard was nothing short of incredible, fantastic, can't wait to take part, when do we begin Phase 3? We were also hearing that these results are even better than what physicians have seen with hormonal therapies. In fact, the hormonal therapy data presented with the newest hormone therapy, estetrol, was much stronger when compared side by side. They are eagerly waiting for our next steps. We held consultant meetings with KOLs at both meetings, and we received a lot of good encouragement to move as fast as we can.
All right, thank you.
Hi, thanks very much. Congratulations on everything you've accomplished. I had a couple of somewhat different questions. The first concerns 992, the new asset, the novel long-acting NK3R asset. Does any of your market research indicate that this longer dosing interval might substantially shift how receptive the market is or how readily that asset gets adopted? And how are you thinking about developing it in parallel? Obviously you have several indications going with 635. I'm not sure whether you might plan one in oncology and one in postmenopause — could you speak to that? Then I have a quick follow-up. Thanks.
Of course, Steve. This is Carl. I'll take a first pass at this, and Sarah may want to chime in afterward. Early on, we conducted market research on 635 in which we asked about how much dosing matters — for example, a pill taken once a day versus an injection given once a month versus one given every three months. Broadly speaking, the pattern showed that most people favored a monthly injectable. That said, those who felt a molecule lasting three months was achievable were quite enthusiastic about it as well; during the interviews, a few patients simply figured it sounded too good to be true. We regard that as a very encouraging sign. When we look at the opportunity in front of us, the first thing I'd say is that we're in an incredible spot — we have this kind of data, with this level of strength, and there aren't many competing molecules out there. We expect some groups will immediately be thinking, "Well, I'm going to follow that up with a half-life extended version." We've had this molecule waiting in the wings, ready to go. We can move it into IND-enabling activities right after the data; we're well ahead of the response we anticipate from the market — that's part of strengthening our position and making sure we get the most out of this opportunity. Beyond making things easier for patients, another factor—and I believe I touched on this briefly in my prepared remarks—is that when the interval between doses is longer, each patient needs fewer administrations. That naturally lowers the cost of goods, and it also helps us meet demand across a wider footprint more readily. We see that as meaningful optionality, at minimum, as this program moves ahead.
Great, thanks Carl. My follow-up is simply that you've got a number of new programs in the pipeline right now. That internal pipeline is growing quite quickly. I was wondering, do you see this as AbCellera having both the wish and the ability to develop all of these as a fully owned, broad internal pipeline, or would you consider, or are you open to, licensing some of these assets out as they move into the clinic and keep progressing? Apart from OX40, since clearly that one is parked for the time being. Thanks.
Sure. What we've said for a while is that we don't want to be a one-trick pony; we want to demonstrate that we can reproducibly generate medicines that are exciting and worth taking into clinical development. You're seeing that now as the pipeline fills up. We have conviction in everything we've brought forward. Naturally, we'll see how they perform, and once we have the early clinical data, that will factor into deciding what to advance. And each time we choose to move a program forward, we have to make a call on resource allocation and bandwidth. As of today, we feel we've got a good handle on this, that we can fund it at the early stage, and that it will create value. We'll keep watching that as we go along. There may well be chances to outlicense; that will depend on the program.
Thank you, Carl.
Great. Appreciate the update and for fitting in our question. Perhaps just to clear my throat on the early next year data update, with that strong 4-week data, and given our understanding of the single dose and the 8-week washout period. I'm just wondering whether it might be possible to observe that at 12 weeks, comparable to orals, and then what does your internal modeling point toward? Then on the open-label extension, you've set a high bar for yourselves, but just regarding the open label, what does the design look like? Might we potentially see some difference between the first 4 weeks and the extension 4 weeks? Thank you.
Hello, Roger. I'll take this question. About our expectations for the 8-week and 12-week points, let me remind everyone that this study involved a single dose, and we expect our strongest results to show up near the 4-week mark. That is why we chose that point as our prespecified time point for efficacy analysis. The reason we kept following patients for efficacy and safety out to 8 and 12 weeks was so we could see how efficacy falls off as exposure falls off, and to build an exposure-response model that would support dose selection. Because there is only one dose, we do not expect efficacy to be maintained over the entire 12 weeks. Actually, if that were the case, constructing the exposure-response model for dose selection would be more difficult. What we want is to observe the drug as it clears, and our half-life has already been disclosed; we anticipate the drug will wash out so we can look at how efficacy shifts, and that backs our model-informed drug development approach. Regarding the 4-week efficacy, it matches what we anticipated for our efficacy data. If you're wondering what we expect in the open label, what we'd hope to see is that placebo patients, when they cross over, experience a comparable level of benefit. That, I think, will give us orthogonal data and provide support. After that, we're eager to report results once those currently undergoing treatment are given their second shot. Early next year will bring data on both how well it works and its safety profile, and in my view this should reinforce our confidence in the program and support advancing it into late-stage development.
Let me just add one more point, Roger. You brought up how efficacy compares with the small molecules; we did say that by week 1, the efficacy we already see appears comparable to those small molecules. As Sarah said, once the drug washes out, efficacy is going to decline. Because we start from such a much better place, we expect to cross over at some point. That isn't the goal, of course. At this stage, our aim isn't to make a drug that matches on efficacy, but one with a formidable efficacy advantage. We intend to preserve that as we settle on the final dosing.
Understood. Many thanks.
Hi there, everyone. We appreciate you fitting in our questions today. When we consider the upcoming data cut from the washout along with the OLE, I'm wondering whether you could speak to how large the OLE portion is — specifically, how many patients have been rolled over into the OLE so far. I have one quick follow-up. Thank you.
Brian, I'll handle that one. I don't want to get ahead of the data we'll be sharing, but what I can say is that uptake of the open-label extension was extremely high, which you might expect given the efficacy results seen at 4 weeks. You will see the vast majority of patients as part of that dataset.
Great. So regarding 992, when you consider the next phase as it advances into later-stage development, what's the endgame for developing 992? Are there particular indications you have in mind that a longer half-life would serve better, or should we view it more as lifecycle management sitting behind 635?
Thanks for the question. As I said, we see a chance to build a product for a broader patient population, one with a longer dosing interval. I think that carries some meaningful commercial advantages; we haven't yet nailed that down, and exactly how we'll position the two products probably isn't something we're ready to discuss today. What I can tell you is that having 992 does not in any way represent a step away from 635; we are fully committed to 635. We believe it will be a terrific product, and we're simply looking to reinforce it with one that's even better and that anticipates how we expect people to respond to it.
Great. I appreciate the extra detail.
Good evening, and thanks for taking my question. I also have a follow-up about 992, if you can tell us which specific modifications were used to extend the half-life. Carl, I wanted to ask about the target half-life or injection interval that you believe would be beneficial here. I'm just curious what that target is. Is it the every 3 months you mentioned? Then I have a follow-up.
Sure. As for the modification, we haven't disclosed anything about the sequence of 992 yet. The engineering methods we've used are widely established and didn't require licensing. We're quite confident things will turn out as we anticipate. On the dosing interval question, ABCL635's original TPP called for once-monthly administration. Clearly, given the results we've presented, we're comfortably within that, so what remains is determining the exact dosing needed to achieve it. Our expectation is that the follow-on product's dosing interval would likely be at least double, maybe triple, or possibly longer, though additional studies are needed to confirm this. I don't want to get ahead of ourselves here.
All right. So perhaps, if we pull back a bit and look at things broadly, given the headway you've achieved on those first 2 in-house programs, I'd be interested to hear your thinking on what the main translation or mechanistic read-through is from those initial programs across to the wider pipeline you have. Many thanks.
Sorry. Would you mind putting that question another way? I don't think I caught the full gist of it.
Sure. I suppose, given what's happened with 635 and 575 and the headway you've made on those, I'm just curious about how that translates to the remainder of your pipeline.
Sure. As I said, what's been achieved with 575 and 635 demonstrates that we've made that shift successfully — going from a platform company to establishing a clinical team and carrying out those programs effectively. With 635, the next major step will be expanding it into late-stage development and being able to move it toward approval. That's the operational read-through. Regarding what it tells us about the platform, 635, in my view, is a solid archetype for the sort of program we're seeking to advance. Biology that's well validated, a substantial unmet need, competition that's very sparse, and a tough target that demands a platform capable of delivering. We have additional programs coming along behind it in that vein. I could point to, for example, 646, which we disclosed today as an antagonist directed at an ion channel target. That's a space we've worked in for quite a while, where we believe our competitive advantage is very strong. Should it advance and eventually become a drug, it would be the first antibody against an ion channel target ever achieved. Getting into that novel target space is certainly something we're focused on. In what is turning into an ever more competitive world, we consider that important.
Hey, everyone. Thanks very much for taking my question, and congrats on all the progress made over the past few months. I just want to get a timeline clarified. As I understand it, the 12-week data were expected in 2026, by the end of that year. Is that correct? And if so, I'm wondering what drove the shift to early 2027? Really, what I'd like to know is whether you have all the data in-house for finalizing the Phase 3 trial design. You're in discussions with regulators; then I have a follow-up question.
Thanks for the question. From an operational standpoint, nothing is unusual. The data are coming in, we're monitoring and analyzing them, and really it comes down to the preferred timing for releasing these data between late 2026 and early 2027. Nothing has fundamentally changed. Do
Do you already have everything you need in-house to lock down the Phase 3 trial design, or is that coming from the talks you're having with regulators?
Regulatory discussions are underway right now, along with KOL discussions regarding how we design our clinical trials. The pathway the two small molecules have laid out strikes me as clear. On the whole, I expect only minor surprises, though there are extra endpoints and design elements, plus sample size and populations, that remain under discussion with them; the feedback we need is fully in hand, but it is moving through regulatory talks, and finalizing our dose requires a bit of time. As that proceeds, we are scaling up manufacturing processes. We stay on track to begin late-stage studies in 2027.
All right, just a quick follow-up. Back in August, if I recall our conversation, you brought up the idea of a head-to-head study. Is an active comparator still something you're thinking about? Or do we need to wait until your trial design is finished?
Right now, we won't be giving out further details on our pivotal study or late-stage designs, though we will be disclosing that over the coming months. Okay.
Thanks a lot.
Thank you, Peter; regarding breast, I believe the general study design can be gathered from the OASIS 4 trial of elinzanetant, in which a pivotal study was run in breast cancer populations, and I would anticipate considerable similarity in that design. As a quick reminder, the treatment effect observed with elinzanetant was highly comparable between VMS linked to naturally occurring menopause and VMS linked to breast cancer treatment. Although we haven't yet studied that patient population, we hold strong conviction that a similarly robust treatment effect will emerge; regarding prostate cancer, far less data exists — some case reports and early studies — and there we'll be doing somewhat more work to define the patient population and the correct study endpoints. There we expect to launch mid-stage studies in 2027. I think the expected treatment effect, based simply on what urologists who have used oral small molecules in patient populations with fairly problematic VMS have told us, has been very encouraging. I think right now we have less of a handle on what the exact patient population should look like, but those discussions are ongoing and very active, and there is certainly a lot of enthusiasm from the field. Great, thank you.
Okay, let me begin with what we're seeing on the market side. Whether much has shifted during the past quarter, I'm not certain, but the change we're observing is a fairly striking shift of focus toward treating VMS. My sense is that this was driven to a considerable degree by the boxed warning being removed from hormone therapy, along with a striking rise in the number of women who are pursuing treatment for problematic VMS and who expect to receive it. For us, that represents a tailwind. Our positioning of the product has never been as a replacement for hormone therapy; instead, we've framed it as an excellent alternative for people who either can't tolerate hormone therapy, have contraindications against it, or simply decide they don't want to take it. Another point I find interesting is how the small molecules have developed, and one dynamic in the market is that there's some — I won't call it friction — but there is some debate regarding risk-benefit and the use of these compared with other therapies serving as non-hormonal options, SSRIs in particular. We believe we have a product here that will show a very clear efficacy advantage, and we intend — or at least we hope — to have a safety profile resembling what it has shown so far. We believe we could be in a position to stand truly alone as an NK3R option and possibly as any option at all for non-hormonal treatment.
Let me jump in on your immunogenicity question. Our confidence, in the end, stems from in silico modeling along with a bit of early preclinical data. In the end, clinical data is what will give us far more confidence. Additional data will arrive as we observe repeat dosing from the open-label extension, and we'll keep monitoring that. Truly, this is something that has to play out through repeat and longer-term studies. Stay tuned, but our current dataset is certainly very encouraging, and nothing in our modeling or in what we've observed preclinically raises any concern for us. Thanks so much.
Thanks a lot for fielding the question, guys, and congratulations on everything you've accomplished here. I'd like to ask about the earlier-stage pipeline. As I understand it, you now have four or five new assets in IND-enabling studies — of those, how many should we reasonably expect to reach maybe Phase 1 over the next year, let's say? I suppose my question is how you're prioritizing when those programs enter the clinic, and maybe what are some of the gating factors that are kind of driving those decisions at this point? Thanks.
Sure. To address your question on the timing of the assets, obviously 635 is a major focus right now. It's the one that has advanced the furthest. Behind it, we're beginning to assemble what we believe is a fairly compelling pipeline. As I mentioned earlier, ABCL688 and 386 are continuing through IND-enabling activities. Both of those carry a timeline that would bring them into the clinic in 2027. Behind them, we've just announced 992; it began IND-enabling activities this past quarter, in Q3, and it will be sometime definitely not in 2027 that it would reach the clinic, but perhaps in 2028; for 646 and 646 and 385, we haven't provided any further guidance, but we will update those as they get closer to clinical development.
Understood, that works well. Thanks.
Wonderful. I appreciate all of you being here today. This has been a strong quarter, and we're eager to talk with you once more in the next quarter.
This concludes today's call. Thank you for attending. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete AbCellera Biologics Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to AbCellera Biologics Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.